Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), Regeneron (REGN)
Analysts fell to the sidelines weighing in on Becton Dickinson (BDX – Research Report) and Regeneron (REGN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Becton Dickinson (BDX)
RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Becton Dickinson on January 20 and set a price target of $210.00. The company’s shares closed last Wednesday at $206.18.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $205.00 average price target, implying a 0.0% downside from current levels. In a report issued on January 17, TipRanks – OpenAI also downgraded the stock to Hold with a $226.00 price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Regeneron on January 20 and set a price target of $745.00. The company’s shares closed last Wednesday at $749.33.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $811.10 average price target, a 10.1% upside from current levels. In a report issued on January 8, Scotiabank also maintained a Hold rating on the stock with a $770.00 price target.
